The Bruyère Deprescribing Research team is very grateful to all those who participated in the Evidence Based Deprescribing Guideline Symposium, which took place from March 26 to 28, 2018, in Ottawa.
The symposium brought together over 135 participants from 100 national and international institutions, across nine countries. Each day of the symposium focused on a different facet of evidence based deprescribing guidelines. The first day, focused on developing new deprescribing guidelines and integrating deprescribing recommendations into existing clinical practice guidelines. The second day, participants turned their attention to the process of implementing deprescribing guidelines, monitoring implementation efforts, and evaluating guideline impact. Participants divided into two streams on the third day, the first stream was a group of educators who were interested in developing deprescribing curricula, while the second stream was a group of researchers who were interested in evaluating implementation of one or more of the deprescribing guidelines. Over the three days, relationships between researchers, clinicians, and community advocates developed and many action items were put forward.
Our diverse and dynamic group of speakers and panelists provided in-depth insight, as well as, actionable and practical tools, methods and research; and were able to share how deprescribing can be used in key areas such as: healthcare, education and outreach.
We are working on transcribing notes from the keynote presentations, breakout sessions and workshops, and once everything has been aggregated we invite you to revisit the website to download the material.
View the symposium agenda and speaker biographies here.
Monday, March 26, 2018 – Speaker Presentations
- Welcome Address: Inaugural experiences developing deprescribing guidelines
Barbara Farrell, BScPhm, PharmD, FCSHP, Scientist, Bruyère Research Institute
- Keynote: Why do we need a high quality method for developing deprescribing recommendations?
Kevin Pottie, MD, MClSc, CCFP, FCFP – Scientist, Bruyère Research Institute and GRADE Working
How do we make sure guidelines are developed efficiently and effectively while meeting the needs of users?
- Health care provider perspective
Candra Cotton, BSc Pharm, BSc Nutrition, clinical pharmacist at the Dr. Everett Chalmers Regional Hospital
- Patient/public perspective
Johanna Trimble, Member, Patients for Patient Safety Canada and the BC Patient Voices Network
- Policy perspective
Barry Jones, BPharm, Senior Policy Analyst, Health Canada
Getting started on an evidence-based clinical guideline (choice of priority therapeutic topic areas – e.g. statins, opioids)
- Toward Future Evidence-Based Deprescribing Guidelines: Getting Started
Lisa McCarthy, BScPhm, PharmD, MSc, Scientist, Women’s College Research Institute at Women’s College Hospital
- Opioid de-prescribing guidelines?
Feng Chang, RPh, BScPhm, PharmD, Associate Professor, School of Pharmacy, University of Waterloo
Tuesday, March 27, 2018 – Speaker Presentations
- Keynote: The long and winding road: moving a good idea into routine practice
Frank Federico, RPh – Executive Director, Strategic Partners, Institute for Healthcare Improvement
- The Italian experience
Vittorio Maio, PharmD, MS, MSPH, Thomas Jefferson University
- The IHI experience in the United States
Tonya Thomas, PharmD. Clinical Pharmacist Ascension Innovator Network member, Institute for Healthcare Improvement
- The Ontario experience
Barbara Farrell, BScPhm, PharmD, FCSHP, Bruyère Deprescribing Guidelines team
- Moving deprescribing forward – what needs to happen so deprescribing becomes a routine part of health care?
Alan Cassels, CD, MPA – Drug Policy Researcher, Faculty of Human and Social Development, University of Victoria
- Why deprescribing is a “wicked” problem and what to do about it
James Conklin, PhD – Associate Professor, Applied Human Sciences at Concordia University
- Changing healthcare provider behaviour: how do psychological approaches help us understand barriers to deprescribing and develop de-implementation interventions?
Nicola McCleary, PhD, Postdoctoral Fellow Clinical Epidemiology Program, Ottawa Hospital Research Institute
- What role can policy play in the implementation of deprescribing initiatives?
Justin Turner, BPharm, MClinPharm, PhD, Senior Advisor, Science Strategy, Canadian Deprescribing Network (CaDeN), Postdoctoral Fellow, Centre de recherche Institut universitaire de gériatrie de Montréal
- Engaging with the public – aiming for collaborative care for deprescribing
Emily Reeve, BPharm(Hons), PhD, Research Fellow, Kolling Institute of Medical Research, Northern Clinical School, Faculty of Medicine, The University of Sydney and Johanna Trimble, Member, Patients for Patient Safety Canada and the BC Patient Voices Network
Wednesday, March 28, 2018 – Speaker Presentations
Lalitha Raman-Wilms, BScPhm, PharmD, FCSHP – Professor and Dean, College of Pharmacy, Rady Faculty of Health Sciences, University of Manitoba
- Keynote: Deprescribing guidelines education and research – the interplay and the way to move forward
Lisa Dolovich, BScPhm, PharmD, MSc – Ontario College of Pharmacists Professorship in Pharmacy Practice, Leslie Dan Faculty of Pharmacy, University of Toronto
- Learning to be a better prescriber
Zubin Austin, BScPhm MBA MISc PhD FCAHS Professor and Murray Koffler Chair in Pharmacy Management
- Participatory vs Expert-led Evaluation: competing factors in guideline implementation and evaluation
Malcolm Maclure, ScD – Academic Chair in Patient Safety and Professor in the Department of Anesthesiology, Pharmacology and Therapeutics at UBC
- Deprescribing Research: Past and Future
Wade Thompson, PharmD, MSc, PhD (Candidate) University of South Denmark
- World Café: Deprescribing research priorities and important outcome measures for developing guidelines